HypertensionSecondary analysis
Atherosclerotic cardiovascular disease modifies ambulatory blood pressure response to mandibular advancement device vs. Continuous positive airway pressure (CPAP) in obstructive sleep apnoea (atherosclerotic cardiovascular disease (ASCVD) modifies blood pressure (BP) response to obstructive sleep apnoea (OSA) therapy)
- Secondary analysis of the CRESCENT randomised trial
- prespecified secondary analysis
- 1:1 randomisation
Authors' conclusion
In patients with OSA and ASCVD, MAD was associated with greater reductions in ambulatory BP than CPAP. Formal evidence of differential treatment effect by ASCVD status was strongest for asleep systolic BP.
Study context
- Population
- Adults with moderate-to-severe OSA and elevated CV risk145 (66%) with ASCVD
- Participants
- 220 adults
- Comparison
- Mandibular advancement device (MAD) vs CPAP, by baseline ASCVD status
- Primary endpoint
- Between-group difference in 24-h ambulatory BP
- Follow-up
- 6 months
Primary result
As reported in the abstract
Ambulatory BP, ASCVD subgroup
MAD vs CPAPDifference, mmHg (95% CI)P value
24-h SBP, ASCVD
−3.41(−6.56 to −0.27)
P = 0.02824-h mean BP, ASCVD
−2.50(−4.90 to −0.11)
P = 0.040asleep SBP, ASCVD
−5.13(−9.36 to −0.91)
P = 0.018asleep mean BP, ASCVD
−3.97(−7.31 to −0.62)
P = 0.021Secondary outcomes
Daytime sleepiness and CV biomarkers
- Treatment effects similar across ASCVD subgroups and treatment groups
Original publication
Atherosclerotic cardiovascular disease modifies ambulatory blood pressure response to mandibular advancement device vs. CPAP in obstructive sleep apnoea (ASCVD modifies BP response to OSA therapy). Eur J Prev Cardiol. Published 12 June 2026. doi:10.1093/eurjpc/zwag297
Summarised from the published abstract; every number is checked against it